Summary:
- A new combination drug therapy has significantly improved the long-term survival rate for patients with advanced melanoma, a deadly form of skin cancer.
- The study found that the combination of the immunotherapy drugs nivolumab and ipilimumab increased the 10-year survival rate to 50% for patients with advanced melanoma, a dramatic improvement over previous treatment options.
- The findings represent a major breakthrough in the treatment of this aggressive cancer, providing new hope for patients with late-stage disease and demonstrating the potential of combination immunotherapies to transform outcomes in oncology.